CIK细胞治疗对晚期恶性肿瘤患者疗效研究

Treatment of CIK cells for advanced malignant tumor patients curative effect research

目的观察自体CIK细胞过继免疫治疗晚期恶性肿瘤患者后,生活质量及相关指标的变化。方法从患者外周血中分离出单个核细胞,加入IFN-γ、抗CD3单抗、IL-2等细胞因子,扩增后CIK细胞分4次回输患者体内,观察患者生活质量、毒副反应及相关指标的改变。结果 38例接受CIK治疗的患者疼痛缓解、体重增加、睡眠改善等明显,毒副反应轻微,差异有统计学意义(P﹤0.05),并且有效率(CR+PR+MR)为66%,肿瘤标记物下降,患者外周血中CD3、CD4 T细胞和NK细胞比例均显著提高(P﹤0.05)。结论自体CIK细胞过继性免疫疗法能显著提高肿瘤患者生活质量,改善临床症状,提高患者免疫功能,对晚期肿瘤病人有积极意义。

Objective： To observe autologous CIK cells to immunotherapy in patients with advanced malignant tumor, quality of life and related index Changes. Methods ： The peripheral blood of patients with isolated mononuclear cells joined IEN-y, anti CD3 monoclonal antibody, cytokines such as IL-2, CIK cells expanded in four transfusion patients, and quality of life, adverse reaction and related indexes were observed in patients. Results ： In 38 patients receiving CIK treatment for pain relief, weight gain and sleep improved significantly, side effects were slight, the difference was statistically significant （ P 〈 0.05）, and efficiency （CR ＋ PR ＋ MR ） of 66%, tumor markers in peripheral blood of patients decreased, CD3, CD4 T and NK cell ratio were significantly increased （ P 〈 0.05 ）. Conclusion： Autologous CIK cell adoptive immunity therapy can significantly increase the cancer patients＇quality of life, improve clinical symptoms and the immune function of patients with advanced cancer patients.